Through its patronage, the Fundación María Cristina Masaveu Peterson has partnered with IMOMA to undertake different research projects which have identified new genes involved in laryngeal cancer. Furthermore, in accelerated ageing they have described new connections between cancer and ageing and have even managed to describe a new disease, Nestor-Guillermo progeria syndrome (NGPS). These discoveries have materialised in the publication of articles in scholarly journals like Science, Cancer Cell, Nature Communications and American Journal of Human Genetics, among others. The description of NGPS brought Dr Cabanillas international recognition in 2012, when he won the Opitz Award. All these scientific achievements are joined by publications in a variety of prestigious journals since IMOMA was created.

Currently, a project is underway to implement the new-generation sequence in clinical practice and apply it to translational research through three avenues of research:

• Development of a new-generation quick sequencing platform for the genetic diagnosis of hereditary deafness and the identification of new genes involved in this pathology.
• Identification and clinical validation of new genes that are potentially involved in prostate cancer.
• Development of a new-generation quick sequencing platform for the genetic diagnosis of hereditary blindness.

This project is the first in a series of initiatives to intensify and spread the application of technology in the clinical and translational fields.